- Pembrolizumab vs chemotherapy in Chinese patients with PD-L1-positive NSCLC: 4-year update from KEYNOTE-042 China studyWu, Yi-Long; Fan, Yun; Zhou, JianYing; Zhang, Li; Zhou, Qing; Li, Wei; Hu, ChengPing; Chen, GongYan; Zhang, Xin; Zhou, CaiCun; Gonzalez Arenas, Carmen; Fu, Wei; Wu, Helen; Mok, TonyAnnual Meeting of the American-Association-for-Cancer-Research (AACR), New Orleans, LA, 2022-04-08 To 2022-04-13.被引 1
- Pembrolizumab vs chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC) and PD-L1 TPS ≥1%: 5-year update from KEYNOTE-042Wu, Y-L.; Zhang, L.; Fan, Y.; Zhou, J.; Zhang, L.; Zhou, Q.; Li, W.; Hu, C.; Chen, G.; Zhang, X.; Zhou, C.; Arenas, C. G.; Chen, Z.; Yu, W. C.; Mok, T. S. K.
- Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): A retrospective real-world study (CTONG2004)Xu, C.; Chen, Q.; Zhou, C.; Wu, L.; Li, W.; Zhang, H.; Li, Y.; Xu, F.; Xiong, J.; Wang, Q.; Zhang, H.; Jiang, Y.; Yin, H.; Wu, Q.; Dai, Q.; Hu, J.; Chen, J.; Zhang, J.; Wu, G.; Wu, Y-L.ESMO Immuno-Oncology Congres, ELECTR NETWORK, 2021-12-08 To 2021-12-11.被引 2
会议论文
Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non-small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).
6被引20阅读
